reference/21602801

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21602801

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	573
issn	1875-8908 1387-2877
issueIdentifier	2
pageRange	557-573
publicationName	Journal of Alzheimer's disease : JAD
startingPage	557
bibliographicCitation	Ketter N, Brashear HR, Bogert J, Di J, Miaux Y, Gass A, Purcell DD, Barkhof F, Arrighi HM. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients. J Alzheimers Dis. 2017;57(2):557–73. doi: 10.3233/jad-160216. PMID: 28269765.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_308365c1137cc26fcd89a0af05216087 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_851d0e02bf35c6e04d43d65992163a05 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-3543-3706 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9e59d444d9138d6ebeb9fee1fb7c4a9a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63eb6f299d7df27ad9f3ea7519e0cd8f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c623d4f52edc7b133cc8f0ad00f2668 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_89a63b798f17411d6d80c9f6d13c4a91 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6605ac72134c9205c7ddc506ee77b0d0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_23b126f14b7f05d88b4b3c25513e5974 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5fcf957ab160dd955b20dc250e2f9a5e
date	2017-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/28269765 https://doi.org/10.3233/jad-160216
isPartOf	https://portal.issn.org/resource/ISSN/1387-2877 https://portal.issn.org/resource/ISSN/1875-8908 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21942
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients
discusses	http://id.nlm.nih.gov/mesh/M0541585 http://id.nlm.nih.gov/mesh/M0011157 http://id.nlm.nih.gov/mesh/M0108562 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0001047
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000544Q000000981 http://id.nlm.nih.gov/mesh/D001921Q000187 http://id.nlm.nih.gov/mesh/D001921Q000000981 http://id.nlm.nih.gov/mesh/D007155Q000627 http://id.nlm.nih.gov/mesh/D061067Q000627 http://id.nlm.nih.gov/mesh/D000544Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D002543Q000000981 http://id.nlm.nih.gov/mesh/D015995 http://id.nlm.nih.gov/mesh/D015994 http://id.nlm.nih.gov/mesh/D002543Q000453 http://id.nlm.nih.gov/mesh/D002543Q000235 http://id.nlm.nih.gov/mesh/D012307 http://id.nlm.nih.gov/mesh/D053208 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D053327Q000235 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D007155Q000009 http://id.nlm.nih.gov/mesh/D000682Q000187 http://id.nlm.nih.gov/mesh/D066127Q000187 http://id.nlm.nih.gov/mesh/D012720 http://id.nlm.nih.gov/mesh/D000544Q000453 http://id.nlm.nih.gov/mesh/D000544Q000235 http://id.nlm.nih.gov/mesh/D006579 http://id.nlm.nih.gov/mesh/D008279 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D061067Q000009 http://id.nlm.nih.gov/mesh/D066127Q000000981
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7215 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d22ef8d03375d89409872210d728cfc0 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6852 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7548

Total number of triples: 65.